GlassScriptPhysician profile
Utpal P Patel
NPI 1306834700
$9,392.49
in general payments reported to CMS, 2019-2025
40 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,507 · 2020: $1,130 · 2021: $1,316 · 2022: $1,047 · 2023: $1,724 · 2024: $1,288 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,327.12 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,566.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,054.60 | 2019-2025 | |
| Astellas Pharma US INC | $995.43 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $720.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $682.47 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $612.55 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $606.55 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $505.47 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $357.57 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $273.94 | 2022-2025 | |
| Boston Scientific Corporation | $251.78 | 2023-2025 | Advantage System, Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Esperion Therapeutics, INC. | $247.93 | 2020-2022 | |
| Lilly USA, LLC | $209.99 | 2019-2025 | Jardiance, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $186.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.42 | 2021-2025 | Xifaxan, Trulance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Utpal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.